www.chronogen.com

Having a remarkable know-how in the genetics of aging, Chronogen has initially developed a series of unique, rapid and reliable screening assays aimed at the identification of small molecule modulators mimicking the genetic effects obtained in C. elegans mutants, or equivalent mouse models. Efforts are now focused on the development of drug candidates which modulate the production of molecules responsible for cardiovascular, metabolic and central nervous system diseases: Reactive Oxygen Species in oxidative stress-related diseases and Lipoproteins in dyslipidemia. Drugs with a new mechanism of action such as cellular oxidative stress modulators are currently in preclinical and clinical development.

PRESS RELEASES

   Chronogen Secures US$3.275MM of Financing From MMV Financial Inc.